N
Nouscom
Tech
Neoantigen Cancer Immunotherapy Reimagined: Safe, Scalable, and Effective
11 employeesFounded 2014
About Nouscom
Swiss biotechnology company Nouscom is developing NOUS-209, an experimental vaccine designed to prevent cancers associated with Lynch syndrome.
IndustryBiotechnology
Size11 employees
Founded2014
HQGlobal
Open Positions
Current hiring status at Nouscom
No open roles currently
There are no published openings right now for Nouscom. Follow this company to receive notifications when new roles open.